We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,900
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Abstract

Purpose: To evaluate the safety and efficacy of subconjunctival injection of low dose mitomycin C (MMC) in the management of pterygium.

Patients and Methods: This study was carried out from February 2006 to April 2007 in the eye clinic of Vali-e-Asr Hospital of Birjand University of Medical Sciences. Forty eyes with primary pterygia received 0.02 mg MMC (0.1 ml of 0.2 mg/ml solution, Kyowa Hakko Kogyo Co. Ltd., Tokyo, Japan) subconjunctivally injected into the body of the pterygium. Patients were followed at one day, one week, one month, six months and one year after injection. Patients were examined at all visits for conjunctivally erythematic, epithelial defects; intraocular pressure; topography; keratometry; and other complications (complete slit-lamp examinations).

Results: The only complications after subconjunctival MMC injection were mild chemosis, long discomfort, and redness in the site of injection for four days, which were seen in six patients (15%). Toxicity of MMC was not observed in any case. The size of pterygia reduced in 83% of cases and progression were not seen in any case. The amount of astigmatism reduced in 70% cases (mean 0.27 diopter).

Conclusion: Subconjunctival injection of MMC is an effective treatment and allows exact titration of MMC delivery to the activated fibroblasts and minimizes epithelial toxicity but long term follow up is required.

Keywords: pterygium, mitomycin C, subconjunctival, complication

1. Introduction

Pterygium is a fibro vascular overgrowth of degenerative conjunctiva tissue that extends across the limbos and invades the cornea [1, 2].
The risk factors for pterygium development include exposure to ultraviolet (UV) light, dust, wind, heat, dryness, and smoke [2].

The primary indication for surgical removal of pterygium is visual acuity reduction. The cause of this phenomenon is extension of remaining scar to visual axis [3]. Irregular astigmatism, reduced vision, discomfort and irritation, difficulty with contact lens wear, refractive surgery, and cosmetic deformity are other reasons for surgical intervention [3].

A wide range of surgical procedures for removal of pterygium have been reported [4]. However, recurrences after excision have been reported to be very high. For example, it has been reported as high as 30% to 80% with the bare sclera technique [5]. The conjunctiva auto graft transplantation effectively prevents pterygium recurrence [6, 7, 8].

MMC is an antibiotic, antineoplastic agent that selectively inhibits the synthesis of DNA, cellular division, and protein [9]. The mechanism of action of MMC seems to be inhibition of fibroblast proliferation at the level of the episclera [10, 11, 12]. The benefit of MMC is having prolonged, but not permanent, effectiveness on suppressing human fibroblasts [13, 14, 15]. Although multiple studies have reported recurrence rates of approximately 5% to 12% with the use of topical MMC [16, 17], this technique has been associated with rare but significant conjunctival and corneal toxicity [16]. In an attempt to decrease ocular morbidity, the intraoperative administration of MMC was applied directly to the sclera bed, which has gained increasing acceptance. Recently, combined pterygium removal with intraoperative MMC and conjunctiva auto grafting for primary and recurrent pterygium has been described [18].

The purpose of this study was to evaluate effectiveness by applying MMC at low concentration and low volume.

2. Patients and methods

Forty consecutive patients (40 eyes) with primary pterygia who attended the eye clinic, Vali-Asr Hospital of Birjand University of Medical Sciences, between 2006 and 2007 were included in this study. All patients had primary pterygium grade I or II and were not previously operated. The grading used was as follows: Grade I: small primary pterygium, fibrous type, pinguecular, and classical type. Grade II: advanced primary pterygium with no optical zone involvement. Grade III: advanced primary pterygium with optical zone involvement. We selected only grade I and II.

A complete ocular examination, including slit-lamp examination and hematological examination, was performed on each patient. All surgeries were performed by one surgeon (Dr. Davari). Satisfaction of Ethical Clearance Committee accepted and all patients were given an explanation of the procedure and informed consent was obtained from all.

A drop of tetracaine 0.5% was instilled in the involved eye for topical anesthesia and the patients were injected subconjunctivally with a 30-gauge needle on an insulin syringe containing 0.1 ml of 0.2 mg/ml of MMC (Kyowa Hakko Kogyo Co. Ltd. Tokyo, Japan). The injection was done directly into the pterygium 1 mm from limbus (Figure 1).
Subconjunctival Mitomycin C Injection into Pterygium Decreases Its Size and Reduces Associated Complications

http://dx.doi.org/10.5772/60090

Figure 1. (a) Subconjunctival injection of MMC directly into pterygium, (b) After injection of MMC the degree of inflammation reduced.

Figure 2. (1A) Before MMC injection, (2A) After MMC injection

Figure 3. (1B) Before MMC injection, (2B) After MMC injection
Figure 4. (a) Before MMC injection, (b) After MMC injection

Figure 5. (a) Before MMC injection, (b) After MMC injection

Figure 6. (a) Before MMC injection, (b) After MMC injection
All patients received one drop of chloramphenicol 0.5% and betamethasone 0.1% eye drops that were instilled four times daily for two days. After injection, patients were followed up at one day, one week, one month, six months, and one year. All patients were examined by a slit lamp at all visits for conjunctiva erythematic, epithelial defects, intraocular pressure, and other complications (complete slit-lamp examinations). The changes of pterygium size were evaluated by biomicroscope measurement (slit-lamp). (Base) × (apex) × (length) vs. mean size before and after MMC injection: (base means: up to down of pterygium in limbos, apex means: end of pterygium in cornea). The changes of refraction were also evaluated with topography and keratometer before and after injection.

Exclusion criteria were collagen vascular disease or other autoimmune diseases; pregnancy; ocular surface pathology or infectious, previous limbal surgery; and type III of pterygium.

3. Result

Of the 40 patients who participated in this study, 18 (45%) were males and 22 (55%) were females. The mean age was 41.50 years. 16 (40%) left eye and 24 (60%) right eye. The patients
were followed up from 12 to 14 months after injection (the mean follow-up period was 12 months). According to this study, 22.50% were farmers, 45% were housewives, and 32.50% had other occupations.

Within 1–3 days after the subconjunctival injection of MMC, 6 patients complained of irritation accompanied with mild conjunctiva swelling, hyperemia, and tearing (15%). These processes were controlled completely by using betamethasone 0.1% more frequently within 1 week. The pterygia were less vascular and less inflamed at the 6th-month visit after MMC injection.

We detected the reduced size of pterygium (mean size before MMC injection: 5.3mm (base) ×2.3 (apex) ×2.4 (length) vs. mean size after MMC injection: 5mm (base) ×2.1mm (apex) ×1.56mm (length)) with mean 0.48 mm (base means: up to down of pterygium in limbus, apex means: end of pterygium in cornea that were evaluated by biomicroscope measurement (slit-lamp)). The size of pterygium was reduced in 83% of cases, and in all cases there were not seen progression and reduced the amount of astigmatism (mean 0.27 diopter) in 70% cases that were evaluated by topography and keratometry [p=0.00] (Table 2). We also detected no significant change in visual acuity and intraocular pressure.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Job</th>
<th>Eyes</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Female</td>
<td>Farmer</td>
<td>Housewives</td>
</tr>
<tr>
<td>Number</td>
<td>18</td>
<td>22</td>
<td>9</td>
</tr>
<tr>
<td>Percent</td>
<td>45%</td>
<td>55%</td>
<td>22.50%</td>
</tr>
<tr>
<td>Total</td>
<td>40</td>
<td>100%</td>
<td>40</td>
</tr>
</tbody>
</table>

Table 1. The prevalence of study participant according to sex, job, age, and affected eye

<table>
<thead>
<tr>
<th>Hyperemia</th>
<th>Tearing</th>
<th>Long discomfort</th>
<th>Subconjunctival hemorrhage</th>
<th>Pigmentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2. Dear Authors, please add Caption

<table>
<thead>
<tr>
<th>Subcategory</th>
<th>Before injection</th>
<th>After injection</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average of size pterygium</td>
<td>2.40</td>
<td>1.56</td>
<td>P=0.00</td>
</tr>
<tr>
<td>Average of refraction</td>
<td>1.19</td>
<td>0.92</td>
<td>P&lt;0.00</td>
</tr>
<tr>
<td>Average of keratometry</td>
<td>1.67</td>
<td>1.33</td>
<td>P&lt;0.00</td>
</tr>
</tbody>
</table>

Table 3. Complication of MMC injection in 6 patients
4. Discussion

Primary pterygium is one of the most common corneal disorders in topical countries such as India and south of Iran [4, 19]. A wide range of surgical procedures for removal of pterygia have been reported over the past decade, and several techniques are now available for the ophthalmic surgeon to choose from [4].

This study evaluated efficacy and complications of subconjunctival injection of MMC in treatment of primary pterygia. In fact, the potent effect of topical MMC on the conjunctiva epithelium has been demonstrated by its ability to prevent the recurrence of conjunctival intraepithelial neoplasia [14]. We use 0.1 ml of 0.2 mg/ml of MMC. Chen et al. [12] showed that a concentration of 0.10 mg/ml MMC inhibits fibroblast replication and that concentrations of 0.3 mg/ml actually cause death of fibroblasts.

Intraoperative use of MMC significantly retards epithelial healing in a dose-related manner in rabbit corneas [15]. In our study, 6 patients complained of irritation accompanied with mild conjunctiva swelling, hyperemia, and tearing (15%). These processes were controlled completely by using betamethasone 0.1% more frequently within one week. The pterygia were less inflamed at the 1st-month visit after MMC injection.

Recently, a new study evaluated adjunctive subconjunctival MMC (0.1 ml of 0.15 mg/ml) before pterygium excision. They reported recurrence rate of 6% with no sever complications [20, 21].

The advantage of low-dose subconjunctival MMC is that it is effective in preventing pterygium recurrence yet avoids the ocular surface toxicity associated with epithelial and bare sclera delivery of the medication. The medication is administered directly to the activated fibroblasts in the subconjunctival space, where it can work to avoid or diminish long-term epithelial healing difficulties associated with MMC. Intraoperative and postoperative MMC are two methods of adjunctive therapy that have been most commonly reported recently [22]. At the present time, we injected low dose subconjunctivally 0.1 ml of 0.2 mg/ml of MMC. Our short-term experience with MMC consistently shows no severe complications and reduces recurrence rate; these findings are similar to the study by Raiskup F et al. in 2004 [22]. Most of the complications of MMC are associated with persistent epithelial defects and ischemic sclera necrosis. Both of these complications are secondary to side effects produced by the direct action of MMC on these tissues. Because the epithelium and sclera are not target tissues for the MMC and because inadvertently treating these tissues does not contribute to the prevention of pterygium recurrence but is associated with significant side effects, the conjunctiva epithelium and sclera should be avoided. With subconjunctival application of MMC, the epithelial and sclera toxicity can be diminished; this occurred in our study. Eric D Donnenfeld et al reported that subconjunctival injection of MMC is an effective treatment before pterygium excision [23]. We chose their method but we used MMC in higher concentration (0.1 ml of 0.2 mg/ml) to reduce the size of pterygium.

In our study, the size of pterygium was reduced in 83% of cases and in all cases there were not seen progression and the amount of Astigmatism reduced (mean 0.27 diopter) in 70% cases
that were evaluated by topography and keratometry (Table 1). In research by Khakshoor H et al, they found that subconjunctival injection of MMC reduced size and recurrence rate of pterygia [24]. Our study shows similar results. Also in another study, Oguz H, in Nassau University Medical Center, East Meadow, New York, USA [25], studied 36 eyes of 36 patients prospectively that received 0.1 ml of 0.15 mg/ml MMC subconjunctivally injected into the head of the pterygium 1 month before bare sclera surgical excision. He reported: the pterygia resolved in 34 (94%) of 36 eyes, with a recurrence rate of 6% over a mean follow-up of 24.4 months. No wound-healing complication developed in any patient. Their findings are similar to our study.

Therefore, low recurrence rate and safety profile with a mean follow-up of longer than 12 months without complication show the efficacy of this treatment and compare favorably with previous studies with MMC in the treatment of pterygia.

Limitation of the study: Despite the fact that we did not observe any significant short-term complications after MMC use, we are aware that only 40 patients were available for evaluation in our study.

We feel that adjunctive use of MMC for pterygium is a safe procedure, but requires a strict selection of patients, controlled use of MMC, and long-term follow-up of these patients. In particular, a very long follow-up of the avascular conjunctival area is required.

5. Conclusion

Subconjunctival injection of MMC is an effective treatment, and that is a promising alternative in the management of pterygium, but long-term follow-up is required.

Author details

Mohammad Hossien Davari1,2, Hoda Gheytasi3* and Esmat Davari1

*Address all correspondence to: hoda24masoud@yahoo.com

1 Ophthalmology Department Vali e Asre Hospital, Birjand University of Medical Science, Birjand, Iran

2 Atherosclerosis and Coronary Artery Research Center, Birjand University of Medical Science, Birjand, Iran

3 Josep Font Laboratory of Autoimmune Disease, IDIBAPS, Hospital Clinic, Barcelona, Spain, Spain
References


